E. Eboulet

发表

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2

A. Addeo, M. Joerger, S. Rothschild, 2020, Cancer Immunology, Immunotherapy.

1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial

C. Britschgi, D. Betticher, M. Joerger, 2020 .

Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial.

T. Ruhstaller, C. Panje, W. Eisterer, 2022, European journal of cancer.

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).

G. Ceresoli, A. Maconi, F. Grosso, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

S. Peters, C. Britschgi, D. Betticher, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma

C. Porta, C. Sternberg, B. Rini, 2020, ESMO Open.

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials

R. Stupp, A. Addeo, D. Betticher, 2022, ESMO open.

Preselection of robust radiomic features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging

S. Peters, M. Guckenberger, S. Tanadini-Lang, 2021, EJNMMI Research.

IMPACT OF EARLY PROPHYLACTIC CRANIAL IRRADIATION WITH HIPPOCAMPAL AVOIDANCE ON NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LIMITED DISEASE SMALL-CELL LUNG CANCER. A MULTICENTER PHASE II TRIAL (SAKK 15/12).

C. B. Rudolf, A. Allal, D. Aebersold, 2020, International journal of radiation oncology, biology, physics.

SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.

S. Peters, C. Britschgi, D. Betticher, 2016 .

Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC

A. Dekker, J. Unkelbach, O. Riesterer, 2021, Scientific Reports.

Radiomics Feature Activation Maps as a New Tool for Signature Interpretability

Stephanie Tanadini-Lang, Jan Unkelbach, Marta Bogowicz, 2020, Frontiers in Oncology.

Impact of CT convolution kernel on robustness of radiomic features for different lung diseases and tissue types.

T. Frauenfelder, M. Guckenberger, S. Tanadini-Lang, 2021, The British journal of radiology.

Extended resection for potentially operable stage III NSCLC patients after neoadjuvant treatment

R. Stupp, R. Stahel, D. Betticher, 2022, The Journal of Thoracic and Cardiovascular Surgery.